BELLEVUE, Wash., Oct. 8, 2026 /PRNewswire/ — Viome PRO, the clinical division of Viome Life Sciences, today launched CancerDetect® Pancreatic, a blood test that looks for pancreatic ductal adenocarcinoma by measuring the enzyme activity associated with the disease. In Viome’s blinded validation, the test detected 86 percent of stage I and II cancers with 90 percent specificity, a performance aimed squarely at the early stages where treatment can still change the outcome. The test is ordered by a physician, drawn as a routine venous sample, and processed in Viome’s CLIA-certified laboratory.